secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2025-09-12T23:59:59+00:00
Accession:  0001193125-25-202366
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam issues $661.25M zero-coupon convertible notes due 2028; repurchases $637.8M of existing notes
--------------------------------------------------------------------------------

- Issued $661.25M aggregate principal of 0.00% Convertible Senior Notes due 2028; initial conversion price $670.11/share (~40% premium).
- Capped call transactions entered to offset dilution; cost $35.3M, cap price $837.61/share (~75% premium).
- Repurchased $637.8M of existing 1.00% convertible notes due 2027 for ~$1,105.8M total (including accrued interest).
- Notes mature Sept 15, 2028, no regular interest; settlement in cash, shares, or combination at Alnylam's election.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000119312525202366/0001193125-25-202366-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000119312525202366/d949176d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-202366

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer